Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Interferon alfa treatment of early primary myelofibrosis is associated with improved overall survival

Katie Erdos, Mlaak Rob, Majed Al-Nazer, Neville Lee, Joseph Scandura, Richard Silver, Ghaith Abu-Zeinah

Blood (2025) 146 (Supplement 1): 2043.

https://doi.org/10.1182/blood-2025-2043

Published: 2025

Journal Articles

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Blood (2025) 146 (Supplement 1): 482.

https://doi.org/10.1182/blood-2025-482

Published: 2025

Journal Articles

Functional annotation of MPN clones reveals mutation-specific fitness and fate bias

Franco Castillo Tokumori, Daniel Choi, Ghaith Abu-Zeinah, Nassima Messali, Maria Yabut, Joseph Scandura

Blood (2025) 146 (Supplement 1): 3766.

https://doi.org/10.1182/blood-2025-3766

Published: 2025

Journal Articles

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Blood (2025) 146 (Supplement 1): 81.

https://doi.org/10.1182/blood-2025-81

Published: 2025

Journal Articles

Real-world temporal evaluation of static risk prediction in polycythemia vera

Katie Erdos, Neville Lee, Yushu Shi, Ghaith Abu-Zeinah, Joseph Scandura

Blood (2025) 146 (Supplement 1): 5594.

https://doi.org/10.1182/blood-2025-5594

Published: 2025

Journal Articles

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Blood (2025) 146 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2025-2018

Published: 2025

Journal Articles

Comprehensive analyses of patient-reported outcomes from the phase 3 VERIFY study of rusfertide or placebo plus current standard of care for polycythemia vera

Aniket Bankar, Andrew Kuykendall, Naveen Pemmaraju, Kristen Pettit, Joseph Shatzel, Alessandro Lucchesi, Valentín García Gutiérrez, Harinder Gill, Joseph Scandura, Francesca Palandri, Matthew Reaney, Cristina Ivanescu, Christina Daskalopoulou, Phil Dinh, Sarita Khanna, Suneel Gupta, Arturo Molina, David Cella

Blood (2025) 146 (Supplement 1): 5588.

https://doi.org/10.1182/blood-2025-5588

Published: 2025

Journal Articles

Achieving JAK2V617F vaf <20% is associated with prolonged event-free survival in polycythemia vera: A milestone of molecular response

Franco Castillo Tokumori, Ghaith Abu-Zeinah, Katie Erdos, Neville Lee, Daniel Choi, Joseph Scandura

Blood (2025) 146 (Supplement 1): 5575.

https://doi.org/10.1182/blood-2025-5575

Published: 2025

Journal Articles

Safety of Cytoreductive Therapy in Younger Patients with Polycythemia Vera: A Systematic Review and Meta-Analysis

Reem S. Chamseddine, Shehroz Rana, Mohammed Khalid, Nicole Kucine, Richard T. Silver, Joseph Scandura, Ghaith Abu-Zeinah

Blood (2022) 140 (Supplement 1): 3999–4000.

https://doi.org/10.1182/blood-2022-168014

Published: 2022

Journal Articles

JAK2 V617F Impairs T Cell Differentiation in Polycythemia Vera

Daniel C Choi, Ghaith Abu-Zeinah, Silvana Di Giandomenico, Katie Erdos, Joseph Scandura

Blood (2022) 140 (Supplement 1): 6746–6747.

https://doi.org/10.1182/blood-2022-167785

Published: 2022

Journal Articles

Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib

Joseph Scandura, Srdan Verstovsek, Marina Kremyanskaya, Moshe Talpaz, Raajit K Rampal, Alessandro Vannucchi, Vikas Gupta, Francesca Palandri, Andrea Patriarca, Prithviraj Bose, Dong Chen, Oksana Zavidij, Jike Cui, Tzuu-Wang Chang, Pietro Taverna, John Mascarenhas, Claire Harrison

Blood (2022) 140 (Supplement 1): 1523–1525.

https://doi.org/10.1182/blood-2022-159409

Published: 2022

Journal Articles

Unbiased Identification of Thrombosis Risk Factors in Polycythemia Vera (PV) Using Machine Learning and Rich Data from Automated Extraction of Medical Records Generates Dynamic Models Highly Predictive for Thrombosis in PV

Ghaith Abu-Zeinah, Spencer Krichevsky, Katie Erdos, Richard T. Silver, Joseph Scandura

Blood (2022) 140 (Supplement 1): 3961–3962.

https://doi.org/10.1182/blood-2022-170893

Published: 2022

Journal Articles

Epigenetic Priming with 5-Azacytidine Prior to Allogeneic Stem Cell Transplantation for Myeloid Malignancies with In Vivo T Cell Depletion: Results of a Phase II Trial

Mohammad Alhomoud, Usama Gergis, Adrienne A. Phillips, Jingmei Hsu, Zhengming Chen, Alexandra Gomez-Arteaga, Tsiporah B. Shore, Joseph Scandura, Koen Van Besien, Sebastian A. Mayer

Blood (2022) 140 (Supplement 1): 7583–7584.

https://doi.org/10.1182/blood-2022-170097

Published: 2022

Journal Articles

Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

Firas El Chaer, James McCloskey, Lindsay A.M. Rein, Randy A. Brown, Steven D. Green, Jeffrey J. Pu, Shuichi Shirane, Kazuya Shimoda, Michiko Ichii, Junichiro Yuda, Joseph Scandura, Sujan Kabir, Jason M Foulks, Jian Mei, Huyuan Yang, Mark Wade, Carl Stapinski, Claudia Lebedinsky, Raajit K Rampal

Blood (2022) 140 (Supplement 1): 594–595.

https://doi.org/10.1182/blood-2022-159086

Published: 2022

Journal Articles

Polycythemia Vera Patients with >20% Reduction in Whole Blood JAK2 V617F Allele Frequency Have Improved Myelofibrosis-Free Survival but Not Overall Survival

Ghaith Abu-Zeinah, Franco Castillo Tokumori, Katie Erdos, Imane Bouhali, Daniel C Choi, Richard T. Silver, Joseph Scandura

Blood (2022) 140 (Supplement 1): 6819–6820.

https://doi.org/10.1182/blood-2022-168283

Published: 2022

Journal Articles

Polycythemia Vera Molecular Response and Its Correlation with Disease Progression: A Systematic Review and Meta-Analysis

Franco Castillo Tokumori, Joseph Scandura, Ghaith Abu-Zeinah

Blood (2022) 140 (Supplement 1): 3993–3994.

https://doi.org/10.1182/blood-2022-170731

Published: 2022

Journal Articles

Diffuse Large B Cell Pdtx in Humanized Mice Are Valuable Models to Study Host-Lymphoma Interactions and Immune-Modulating Agents

Giorgia Zanetti, Giuseppina Astone, Luca Cappelli, William Chiu, Maria Teresa Cacciapuoti, Clarisse Kayembe, Danilo Fiore, Wayne Tam, Joseph Scandura, Silvana Di Giandomenico, Lorenzo Galluzzi, Lisa Giulino Roth, Giorgio Inghirami

Blood (2021) 138 (Supplement 1): 2406.

https://doi.org/10.1182/blood-2021-151598

Published: 2021

Journal Articles

Splenomegaly (SPML) in Polycythemia Vera (PV): Its Clinical Significance and Relation to Myelofibrosis and Survival

Richard T. Silver, Elwood Taylor, III, Joseph Scandura, Ghaith Abu-Zeinah

Blood (2021) 138 (Supplement 1): 2580.

https://doi.org/10.1182/blood-2021-149137

Published: 2021

Journal Articles

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

Blood (2021) 138 (Supplement 1): 2583.

https://doi.org/10.1182/blood-2021-150561

Published: 2021

Journal Articles

Normal Life Expectancy for Polycythemia Vera Patients Is Possible

Ghaith Abu-Zeinah, Richard T. Silver, Khalid Abu-Zeinah, Joseph Scandura

Blood (2021) 138 (Supplement 1): 2575.

https://doi.org/10.1182/blood-2021-147061

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Interferon alfa treatment of early primary myelofibrosis is associated with improved overall survival

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Functional annotation of MPN clones reveals mutation-specific fitness and fate bias

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Real-world temporal evaluation of static risk prediction in polycythemia vera

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Comprehensive analyses of patient-reported outcomes from the phase 3 VERIFY study of rusfertide or placebo plus current standard of care for polycythemia vera

Achieving JAK2V617F vaf <20% is associated with prolonged event-free survival in polycythemia vera: A milestone of molecular response

Safety of Cytoreductive Therapy in Younger Patients with Polycythemia Vera: A Systematic Review and Meta-Analysis

JAK2 V617F Impairs T Cell Differentiation in Polycythemia Vera

Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib

Unbiased Identification of Thrombosis Risk Factors in Polycythemia Vera (PV) Using Machine Learning and Rich Data from Automated Extraction of Medical Records Generates Dynamic Models Highly Predictive for Thrombosis in PV

Epigenetic Priming with 5-Azacytidine Prior to Allogeneic Stem Cell Transplantation for Myeloid Malignancies with In Vivo T Cell Depletion: Results of a Phase II Trial

Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

Polycythemia Vera Patients with >20% Reduction in Whole Blood JAK2 V617F Allele Frequency Have Improved Myelofibrosis-Free Survival but Not Overall Survival

Polycythemia Vera Molecular Response and Its Correlation with Disease Progression: A Systematic Review and Meta-Analysis

Diffuse Large B Cell Pdtx in Humanized Mice Are Valuable Models to Study Host-Lymphoma Interactions and Immune-Modulating Agents

Splenomegaly (SPML) in Polycythemia Vera (PV): Its Clinical Significance and Relation to Myelofibrosis and Survival

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

Normal Life Expectancy for Polycythemia Vera Patients Is Possible

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only